NCI operational task order, FY26-FY27
Active Awarded Last action
- Contract number
- 75N91025F00016
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $825,985,691
Award facts
- Contract value 98% obligated
- $844,044,838.32 Current and potential, with all options
- Completion date 57% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21701, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $342,194,143 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | -$1,700,000 | |
| Exercise an Option | $113,704,173 | |
| Funding Only Action | $29,536,535 | |
| Other Administrative Action | $4,339,188 | |
| Funding Only Action | $10,783,972 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $221,191 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $271,036,257 | |
| Original award | $55,870,232 |
Show all 14
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on August 31, 2025, with a ceiling value of $844.0 million and an ultimate completion date of August 30, 2027, for NCI operational task-order work in fiscal years 2026 and 2027.
The order is issued under the NCI master indefinite delivery contract (75N91019D00024) and carries cost-plus-fixed-fee pricing. Place of performance is Frederick, Maryland. The scope encompasses research and operational support across multiple scientific domains at the Frederick National Laboratory for Cancer Research and subordinate NIH institutes.
In fiscal year 2025, Leidos Biomedical Research invoiced $36.5 million on this order across 65.8 FTEs and 136,801 contractor hours, yielding a blended government-paid rate of $266.93 per hour. The company engaged four subcontractors representing 9 percent of contractor hours; named teaming partners include Abbott Molecular Inc., Tecan U.S. Inc., and Brooks Instrument LLC for laboratory diagnostics, automation, and instrumentation support.
Quick answers
Who was awarded contract 75N91025F00016?
75N91025F00016 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 31, 2025.
How much is contract 75N91025F00016 worth?
The government has obligated $825,985,691 on 75N91025F00016. Its current value, with exercised options, is $844,044,838.
Is contract 75N91025F00016 an order under another contract?
Yes. 75N91025F00016 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00016 competed?
The extent of competition for 75N91025F00016 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award